ImmuPharma
Quick facts
Phase 3 pipeline
- IPP-201101 · Immunology
IPP-201101 is an immunomodulatory compound designed to enhance immune responses against disease targets.
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors: